https://orcid.org/0000-0001-8513-550X
Figures & data
Table 1. Baseline demographics and disease characteristics and disease activity.
Table 2. Overview of safety measures including drug exposure, treatment-emergent adverse events, and adverse events of special interest.
Table 3. Adverse events detail.
Figure 1. Mean changes for laboratory values from baseline to 120 weeks therapy with 2 mg and 4 mg baricitinib.
Supplemental Material
Download PDF (180 KB)Data availability statement
Eli Lilly and Company provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the United States and the European Union and after primary publication acceptance, whichever is later. No expiration date of data requests is currently set once data are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, and blank or annotated case report forms, will be provided in a secure data sharing environment. For details on submitting a request, see the instructions provided at www.vivli.org.